Seller record · Telehealth service

Edessa

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 1 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published. The footer says the company receives testing reports from its pharmacies, and none is reachable on the product pages, the about page or the terms.

At a glance

EdessaTelehealth service

7/8criteria passed

Price: Semaglutide from $135 a month, tirzepatide from $209
Sells: compounded semaglutide injection, GLP-1 tablets, and 1 more
FDA letters: None on file

Visit Edessa See all eight dispositions

Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.

A Las Vegas-based telehealth weight loss program selling compounded semaglutide injections and dissolving tablets and compounded tirzepatide on 1, 3 or 6-month plans, with care from a contracted network of US-licensed doctors and a money-back guarantee. Care starts with a free online assessment, and its terms name three partner pharmacies with addresses.

Operating entity Edessa Group, LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Edessa's product GLP-1 injection page; Edessa's website
S2	Prescription gating	PASS	Edessa's product GLP-1 injection page; Edessa's website
S3	Pharmacy identification	PASS	Edessa's terms and conditions
S4	Compounding disclosure	PASS	Edessa's product GLP-1 injection page; Edessa's product GLP-1 tirzepatide page
S5	Analytical documentation	FAIL	Edessa's website; Edessa's about page
S6	Business address	PASS	Edessa's terms and conditions; Edessa's website
S7	Price disclosure	PASS	Edessa's product GLP-1 injection page; Edessa's product GLP-1 tablet page; Edessa's product GLP-1 tirzepatide page; Edessa's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed medical provider reviews each assessment and decides whether the medication is right for the patient, and the footer says the telehealth network OpenLoop Health sets the criteria and its US-licensed doctors decide on prescriptions.Source: Edessa's product GLP-1 injection page; Edessa's website.

S2PASSThe product pages set out the order as a free online medical intake first, then a licensed provider's review, then delivery only if prescribed, and the answers say providers review the answers from the online visit before prescribing.Source: Edessa's product GLP-1 injection page; Edessa's website.

S3PASSThe terms list three partner pharmacies with street addresses: RedRock Pharmacy, 1240 E 100 S #220, St. George, UT 84790; Health Warehouse, 7107 Industrial Rd., Florence, KY 41042; and Precision Compounding Pharmacy, 2657 Merrick Road, Bellmore, NY 11710.Source: Edessa's terms and conditions.

S4PASSEach product page states that compounded products are not approved nor evaluated for safety, efficacy or quality by the FDA, and the safety information on the same page says compounded medications are not FDA-approved.Source: Edessa's product GLP-1 injection page; Edessa's product GLP-1 tirzepatide page.

S5FAILNo certificate of analysis or lot document is published. The footer says the company receives testing reports from its pharmacies, and none is reachable on the product pages, the about page or the terms.Source: Edessa's website; Edessa's about page.

S6PASSEdessa Group, LLC at 732 S 6th St, Ste N, Las Vegas, NV 89101, printed in the footer of every page and as the notice address in the terms. The terms name the courts of Clark County, Nevada.Source: Edessa's terms and conditions; Edessa's website.

S7PASSCompounded semaglutide injections cost $135 a month on the 6-month plan, $160 on the 3-month plan and $179 month to month; GLP-1 tablets $199, $209 or $229; and compounded tirzepatide $209, $219 or $239. The answers give $135 as the lowest price for the opening month and for refills, covering the provider review, the medication and shipping.Source: Edessa's product GLP-1 injection page; Edessa's product GLP-1 tablet page; Edessa's product GLP-1 tirzepatide page; Edessa's website.

S8PASSNo FDA warning letter names Edessa, Edessa Group, LLC or Edessa Health, Inc., and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injection, GLP-1 tablets, compounded tirzepatide injection.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Edessa

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.